Related Experiment Video
Updated: Apr 3, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Matrix-remodeling associated 5 as a novel tissue biomarker predicts poor prognosis in non-small cell lung cancers
1Department of Cardiothoracic surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Background:
Matrix-remodeling associated 5 (MXRA5) has recently been one of the frequently mutated gene but its role in non-small cell lung cancer (NSCLC) remains unclear.
Objective:
To identify whether MXRA5 could be applied as a novel prognostic marker for NSCLC.
Methods And Results:
In this study, we proved that mRNA and protein expression of MXRA5 in 166 NSCLC patients' tissues by Quantitative Real-Time PCR and immunohistochemical staining respectively. Moreover, the correlation between MXRA5 protein expression and clinicopathological features and prognosis in NSCLC patients was evaluated. Our results revealed that the over-expression of MXRA5 was significantly correlated with age (P = 0.049), differentiation (P = 0.003), tumor-node-metastasis (TNM) stage (P = 0.017) and smoking cigarette (P = 0.007). In addition, it also showed that patients with higher MXRA5 protein expression had significantly shorter overall survival (P < 0.001). Multivariate analysis indicated that over-expression of MXRA5 protein was an independent prognostic factor for NSCLC.
Conclusions:
MXRA5 protein is aberrantly expressed in NSCLC and the high MXRA5 expression is correlated with tumor progression and overall survival. These results indicated the potential value of MXRA5 as a novel therapeutic target for the treatment of NSCLC.
